Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
1-50 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__175_A1,1 | Lung | Primary cancer | 3,505 | Tumor/Malignant | 61.6% | 0.97 | 0.15 |
| NSCLC_38242124__IMC__175_A1,10 | Lung | Primary cancer | 4,001 | Tumor/Malignant | 51.2% | 0.89 | 0.34 |
| NSCLC_38242124__IMC__175_A1,11 | Lung | Primary cancer | 3,063 | Tumor/Malignant | 68.9% | 0.94 | 0.18 |
| NSCLC_38242124__IMC__175_A1,12 | Lung | Primary cancer | 3,476 | Tumor/Malignant | 45.1% | 0.98 | 0.10 |
| NSCLC_38242124__IMC__175_A1,13 | Lung | Primary cancer | 4,327 | Tumor/Malignant | 51.9% | 0.96 | 0.12 |
| NSCLC_38242124__IMC__175_A1,14 | Lung | Primary cancer | 3,473 | Tumor/Malignant | 38.6% | 0.93 | 0.30 |
| NSCLC_38242124__IMC__175_A1,15 | Lung | Primary cancer | 3,465 | Other | 37.5% | 0.94 | 0.17 |
| NSCLC_38242124__IMC__175_A1,16 | Lung | Primary cancer | 2,287 | Tumor/Malignant | 65.5% | 0.93 | 0.20 |
| NSCLC_38242124__IMC__175_A1,17 | Lung | Primary cancer | 1,704 | Stromal | 32.9% | 0.73 | 0.63 |
| NSCLC_38242124__IMC__175_A1,2 | Lung | Primary cancer | 4,320 | Tumor/Malignant | 38.0% | 0.40 | 0.98 |
| NSCLC_38242124__IMC__175_A1,3 | Lung | Primary cancer | 2,452 | Tumor/Malignant | 58.1% | 0.96 | 0.15 |
| NSCLC_38242124__IMC__175_A1,4 | Lung | Primary cancer | 3,563 | Tumor/Malignant | 43.1% | 0.94 | 0.18 |
| NSCLC_38242124__IMC__175_A1,6 | Lung | Primary cancer | 2,595 | Tumor/Malignant | 53.2% | 0.97 | 0.14 |
| NSCLC_38242124__IMC__175_A1,7 | Lung | Primary cancer | 3,404 | Other | 45.0% | 0.90 | 0.30 |
| NSCLC_38242124__IMC__175_A1,8 | Lung | Primary cancer | 1,375 | Tumor/Malignant | 81.8% | 0.98 | 0.06 |
| NSCLC_38242124__IMC__175_A1,9 | Lung | Primary cancer | 4,192 | Tumor/Malignant | 67.0% | 1.00 | 0.03 |
| NSCLC_38242124__IMC__175_A2,1 | Lung | Primary cancer | 3,092 | Tumor/Malignant | 51.4% | 0.99 | 0.02 |
| NSCLC_38242124__IMC__175_A2,10 | Lung | Primary cancer | 3,762 | Tumor/Malignant | 37.2% | 0.89 | 0.36 |
| NSCLC_38242124__IMC__175_A2,11 | Lung | Primary cancer | 2,845 | Tumor/Malignant | 42.7% | 0.90 | 0.27 |
| NSCLC_38242124__IMC__175_A2,12 | Lung | Primary cancer | 2,805 | Tumor/Malignant | 63.6% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__175_A2,13 | Lung | Primary cancer | 3,133 | Tumor/Malignant | 74.6% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__175_A2,14 | Lung | Primary cancer | 4,276 | Immune | 30.7% | 0.94 | 0.21 |
| NSCLC_38242124__IMC__175_A2,15 | Lung | Primary cancer | 1,106 | Tumor/Malignant | 42.1% | 0.85 | 0.32 |
| NSCLC_38242124__IMC__175_A2,16 | Lung | Primary cancer | 3,193 | Tumor/Malignant | 58.0% | 0.94 | 0.19 |
| NSCLC_38242124__IMC__175_A2,17 | Lung | Primary cancer | 1,862 | Tumor/Malignant | 27.0% | 0.51 | 0.85 |
| NSCLC_38242124__IMC__175_A2,2 | Lung | Primary cancer | 2,812 | Tumor/Malignant | 32.6% | 0.94 | 0.22 |
| NSCLC_38242124__IMC__175_A2,3 | Lung | Primary cancer | 2,411 | Tumor/Malignant | 68.3% | 0.98 | 0.11 |
| NSCLC_38242124__IMC__175_A2,4 | Lung | Primary cancer | 3,408 | Tumor/Malignant | 72.3% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__175_A2,5 | Lung | Primary cancer | 2,461 | Tumor/Malignant | 27.5% | 0.86 | 0.35 |
| NSCLC_38242124__IMC__175_A2,6 | Lung | Primary cancer | 2,583 | Tumor/Malignant | 38.1% | 0.75 | 0.54 |
| NSCLC_38242124__IMC__175_A2,7 | Lung | Primary cancer | 3,569 | Tumor/Malignant | 38.5% | 0.50 | 0.81 |
| NSCLC_38242124__IMC__175_A2,8 | Lung | Primary cancer | 1,237 | Tumor/Malignant | 65.7% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__175_A2,9 | Lung | Primary cancer | 4,350 | Tumor/Malignant | 71.5% | 0.97 | 0.11 |
| NSCLC_38242124__IMC__175_A3,1 | Lung | Primary cancer | 3,603 | Tumor/Malignant | 40.9% | 0.76 | 0.61 |
| NSCLC_38242124__IMC__175_A3,10 | Lung | Primary cancer | 3,114 | Tumor/Malignant | 42.5% | 0.93 | 0.26 |
| NSCLC_38242124__IMC__175_A3,11 | Lung | Primary cancer | 3,134 | Tumor/Malignant | 46.6% | 0.96 | 0.12 |
| NSCLC_38242124__IMC__175_A3,12 | Lung | Primary cancer | 1,916 | Tumor/Malignant | 47.3% | 0.90 | 0.32 |
| NSCLC_38242124__IMC__175_A3,13 | Lung | Primary cancer | 4,214 | Stromal | 64.3% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__175_A3,14 | Lung | Primary cancer | 3,209 | Tumor/Malignant | 45.9% | 0.94 | 0.21 |
| NSCLC_38242124__IMC__175_A3,15 | Lung | Primary cancer | 2,343 | Stromal | 35.3% | 0.89 | 0.27 |
| NSCLC_38242124__IMC__175_A3,16 | Lung | Primary cancer | 3,374 | Tumor/Malignant | 36.2% | 0.95 | 0.20 |
| NSCLC_38242124__IMC__175_A3,17 | Lung | Primary cancer | 2,434 | Tumor/Malignant | 37.9% | 0.86 | 0.37 |
| NSCLC_38242124__IMC__175_A3,2 | Lung | Primary cancer | 1,903 | Tumor/Malignant | 40.0% | 0.77 | 0.57 |
| NSCLC_38242124__IMC__175_A3,3 | Lung | Primary cancer | 1,345 | Stromal | 47.4% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__175_A3,4 | Lung | Primary cancer | 2,091 | Stromal | 25.6% | 0.84 | 0.36 |
| NSCLC_38242124__IMC__175_A3,5 | Lung | Primary cancer | 1,902 | Tumor/Malignant | 51.4% | 0.93 | 0.22 |
| NSCLC_38242124__IMC__175_A3,6 | Lung | Primary cancer | 3,058 | Tumor/Malignant | 41.0% | 1.00 | 0.03 |
| NSCLC_38242124__IMC__175_A3,7 | Lung | Primary cancer | 2,576 | Tumor/Malignant | 54.5% | 0.93 | 0.22 |
| NSCLC_38242124__IMC__175_A3,8 | Lung | Primary cancer | 2,287 | Tumor/Malignant | 52.5% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__175_A3,9 | Lung | Primary cancer | 3,607 | Stromal | 33.8% | 0.42 | 0.83 |